AGEN Agenus Inc.

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report

Conference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET

LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call

Dial-in numbers: (646) 307-1963 (US-NY) or (800) 715-9871 (US & CA)

Event ID: 6683845

Webcast

A webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at  and via .

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact

Agenus Inc.

Ethan Lovell

Chief External Affairs & Communications Officer

339-927-1763



EN
27/07/2022

Underlying

AGENAgenus Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agenus Inc.

Free Trial
AGEN AGENUS INC.

Agenus Inc: 1 director

A director at Agenus Inc bought 500,000 shares at 0.648USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

02/16/24 February 16, 2024 1 EN
 PRESS RELEASE
Free
AGEN AGENUS INC.

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and...

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven additional metastatic, late-line cancers in a total of more than 300 patientsRandomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer,...

March 14, 2023 1 EN
 PRESS RELEASE
Free
AGEN AGENUS INC.

Agenus Cancels Conference Call to Discuss the Company’s Minority Cash ...

Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement Conference Call Cancelled LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it has cancelled its conference call on Monday, March 13th to discuss its minority cash holdings at Silicon Valley Bank (SVB) in light of the government’s SVB deposit access announcement. About Agenus...

March 13, 2023 1 EN
 PRESS RELEASE
Free
AGEN AGENUS INC.

Agenus Schedules Conference Call to Discuss the Company’s Minority Cas...

Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced that it will hold a conference call to provide detail and to answer any questions regarding its minority cash holdings at Silicon Valley Bank (SVB) at 8:30 a.m. ET on Monday, March 13th. Conference CallDial-in numbers: (646) 307...

March 11, 2023 1 EN
 PRESS RELEASE
Free
AGEN AGENUS INC.

Agenus to Present Botensilimab Data in Oral Plenary Session at the Soc...

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL. Updated data from an expansion...

February 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch